Health ❯Healthcare ❯Medical Research ❯Clinical Trials
Phase III data validate December’s accelerated FDA decision by confirming the encorafenib, cetuximab and mFOLFOX6 combination as a new standard of care for this aggressive molecularly defined disease.
